RCT of TJ-3020 in patients with unresectable advanced or recurrent pancreatic cancer receiving nab-Paclitaxel plus Gemcitabine
Phase 2
Recruiting
- Conditions
- Pncreatic cancerPancreatic cancer
- Registration Number
- JPRN-jRCTs041190040
- Lead Sponsor
- Kodera Yasuhiro
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 56
Inclusion Criteria
Unresectable or relapse pancreatic cancer
Exclusion Criteria
Herbal medicine Allergies
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of fatigue and Malaise
- Secondary Outcome Measures
Name Time Method Assessment of QOL, Assesment of pain, Relative dose intensity